Improving antibiotic choices for cancer patients with reported penicillin allergies
Official title: Optimizing antibiotic selection in hematologic malignancy patients with reported beta-lactam allergy
Funded at University of Pennsylvania · NIH-11077256 · Data updated 2026-11-12
This study is looking to help patients with blood cancers who are at risk for infections by finding better ways to choose antibiotics, especially for those who might have been wrongly labeled as allergic to certain medications, so they can receive safer and more effective treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | May 1, 2024 |
| Project end | February 28, 2029 |
| Funding year | 2025 |
| Award (this year) | $249,755 |
| NIH project number | 5R01HS029879-02 |
| Project ID | NIH-11077256 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with hematologic malignancies who have reported beta-lactam allergies.
✕Less likely to help
Patients without hematologic malignancies or those who do not have a reported beta-lactam allergy may not benefit from this research.
What this research studies
This research focuses on patients with hematologic malignancies who are at high risk for infections and complications due to prolonged antibiotic use. It aims to optimize antibiotic selection by addressing the common issue of inaccurate beta-lactam allergy labels, which can lead to the use of less effective and more harmful antibiotics. The study will explore interventions such as patient history reviews, skin testing, and oral challenges to safely delabel patients who are inaccurately labeled as allergic. By improving antibiotic stewardship, the research seeks to enhance treatment outcomes for these vulnerable patients.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective antibiotic treatments for cancer patients, reducing complications and improving survival rates.
How similar studies have gone: Previous studies have shown that interventions to delabel antibiotic allergies can significantly improve antibiotic use and clinical outcomes in hospitalized patients.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Lautenbach, Ebbing — University of Pennsylvania
- Study coordinator: Lautenbach, Ebbing
Related research
Other NIH-funded projects on the same topics.
-
Safer antibiotic choices for people with blood cancers and reported penicillin/beta‑lactam allergy
This project helps people with blood cancers who report a penicillin or related antibiotic allergy learn whether they can safely use those drugs so they can get the most effective antibiotics.
-
How early gut bacteria affect the risk of fever and infections in blood cancer patients
This study is looking at how the bacteria in your gut might affect your chances of getting fevers and infections while you're being treated for blood cancers, so we can tailor antibiotic treatments just for you and help you feel better faster.
-
New Horizons in preventing and treating food allergy
A Johns Hopkins-led effort aims to advance how we prevent and treat food allergies across all ages by coordinating high-quality studies and developing better therapies.
-
Understanding antibiotic allergy to improve care for patients
Scientists are testing new ideas to understand why some people develop severe allergic reactions to antibiotics and how to prevent or treat them.
-
Antibiotic Allergy: Types, Triggers, and How they Work
This grant aims to better understand why certain antibiotics trigger immediate allergic reactions and how to improve testing and diagnosis for patients with suspected antibiotic allergies.
-
Understanding alpha-gal meat allergy and how the body's immune system reacts
This grant studies why some people develop a dangerous allergy to meat due to a molecule called alpha-gal and how it triggers life-threatening reactions.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.